Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25226991 | 0.73 | AURKA (0.34) | MEN1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL20980282 | 0.72 | MEN1 (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13326638 | 0.71 | SYK (0.44) | KDM4E | |
| SCHEMBL26341326 | 0.69 | MEN1 (0.55) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL20980240 | 0.68 | KMT2A (0.39) | MEN1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL8397028 | 0.66 | KMT2A (0.42) | MEN1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL8402430 | 0.65 | CLK1 (0.38) | POLB | |
| SCHEMBL27755208 | 0.64 | POLB (0.42) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7113348 | 0.63 | KMT2A (0.41) | MEN1KMT2AALDH1A1GAAKDM4E | |
| SCHEMBL1884340 | 0.62 | PARP1 (0.40) | MEN1KMT2AALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | MEN1 1959/4885KMT2A 1422/4885ALDH1A1 1403/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | MEN1 1959/4885KMT2A 1422/4885ALDH1A1 1403/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | MEN1 2417/4885KMT2A 1381/4885ALDH1A1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.